Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Key Inclusion Criteria:

• Diagnosis of PsA as classified by CASPAR criteria for at least 6 months beforerandomization.

• Active PsA at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen jointsout of 66 (dactylitis of a digit counts as one joint each).

• Inadequate response or intolerance to previous or current treatment with at leastone TNFα inhibitor

• Inadequate response or intolerance to conventional disease modifying anti-rheumaticdrugs (cDMARDs)

• Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cmdiameter and/or nail changes consistent with psoriasis and/or documented history ofplaque psoriasis.

• Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodiesnegative at screening.

Key Exclusion Criteria:

• Pregnant or nursing women,

• Previous exposure to secukinumab, ustekinumab or any other biologic drug directlytargeting IL-17, IL-17 receptor, IL-12 or IL-23.

• Patients for whom the use of secukinumab or ustekinumab is contraindicated.

• Use of any other investigational drug. Previous treatment with any cell-depletingtherapies including but not limited to anti-CD20 or investigational agents

• Evidence of ongoing infectious or malignant process

• Subjects receiving high potency opioid analgesics

• Ongoing use of prohibited psoriasis treatments/medications

Other protocol-defined inclusion/exclusion criteria may apply